Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity

Benjamin Peschke1, Christian W. Keller1, Patrick Weber1, Isaak Quast1,2† and Jan D. Lünemann1,3*,†

1 Institute of Experimental Immunology, Laboratory of Neuroinflammation, University of Zurich, Zurich, Switzerland,
2 Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia,
3 Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Binding of the complement component C1q to the CH2 domain of antigen-bound immunoglobulin gamma (IgG) activates the classical complement pathway and depends on its close proximity to Fc fragments of neighboring antibodies. IgG subclasses contain a highly conserved asparagine 297 (N)-linked biantennary glycan within their CH2 domains, the core structure of which can be extended with terminal galactose and sialic acid residues. To investigate whether Fc-glycosylation regulates effector functions of human IgG subclasses, we cloned the antigen-binding region of the CD20-specific monoclonal antibody rituximab into IgG isotype expression vectors. We found that Fc-galactosylation enhances the efficacy of CD20-targeting complement-fixing antibodies for C1q binding and complement-mediated tumor cell lysis. Increased efficacies were restricted to IgG1 and IgG3 subclasses indicating that Fc-galactosylation alone is not sufficient for IgG2 and IgG4 to acquire complement-fixing properties. Addition of terminal galactose to the N-glycan specifically improved binding of C1q without changing antigen- and FcγRIIIa-binding affinities of IgG isotypes. These data indicate that Fc galactosylation can be harnessed to enhance the complement-activating properties of IgG1 and IgG3 antibodies.

Keywords: C1q, complement system proteins, antibodies, monoclonal, glycan, IgG subclasses

INTRODUCTION

Immunoglobulin gamma (IgG) antibodies are preeminent effector proteins of the immune system. The bimodal architecture of IgG allows for simultaneous recognition of antigen (by the antigen-binding fragment, Fab) and the initiation of IgG effector functions such as recruitment and activation of leukocytes and antibody-dependent cell-mediated cytotoxicity (ADCC) through interaction with FcγRs as well as complement activation through binding of the constant, crystallizable fragment (Fc) binding of C1q. Human IgG is subdivided in the four isotypes IgG1 to IgG4, numbered based on their abundance in serum (1). Despite being more than 90% identical in amino acid sequence, IgG isotypes differ in key functional regions responsible for flexibility, FcγR binding, and complement fixation (2).

All IgG subclasses contain a highly conserved asparagine-linked (N-)oligosaccharide located in the CH2 domain of the Fc region. Presence of this glycan serves important functions in protein
folding and post-translational quality control mechanisms and is essential for antibody-mediated effector functions (3, 4). The biantennary core glycan structure, which is composed of two N-acetylglucosamines (GlcNAc) and three mannose residues, can be further decorated with fucose, bisecting GlcNAc and terminal GlcNAc, galactose, and sialic acid. The highest degree of variability among IgG antibodies stems from the presence or absence of galactose with around 40% containing one galactose, 20–40% two galactoses, and the remainder none (5–7).

Presence or absence of distinct N-glycan residues such as fucose and sialic acid can dramatically alter pro- and anti-inflammatory IgG activities. Removal of the fucose residue from human IgG1 increases antibody-dependent cell-mediated cytotoxicity (ADCC) through improved affinity for Fcγ receptor IIIa (FcγRIIIa) (8, 9). We have previously shown that IgG Fc sialylation of human monoclonal IgG1 molecules impairs their efficacy to induce complement-dependent cytotoxicity (CDC) (10). Here, we determined whether Fc galactosylation of human IgG isotypes (IgG1–4) regulates antibody effector functions.

RESULTS

Generation of Degalactosylated and Galactosylated IgG Isotypes Targeting CD20

To test the impact of Fc galactosylation of human IgG isotypes on target cell depletion, we first cloned the sequence encoding the heavy chain (HC) and light chain (LC) antigen-binding regions of the monoclonal CD20-targeting antibody rituximab into human IgG1–4 HC and kappa LC expression vectors. Plasmids were cotransfected in HKB11 cells and antibodies were purified from the supernatant using protein G columns. Next, we either treated the antibodies with recombinant galactosidase to completely remove galactose or with β-1,4-galactosyltransferase in the presence of uridine diphosphate (UDP-)galactose to obtain galactosylated antibodies. After repurification, antibodies were analyzed for purity and integrity by gel electrophoresis and immunoblotting with the galactose-specific Erythrina Cristagalli lectin to confirm the successful generation of glycovariants (Figure 1).
Addition or Removal of IgG-Fc Galactose Does Not Affect Antigen Binding

Modifications in the Fc domain may change the structural properties of the antibody, potentially leading to changes in its antigen-binding region. To determine antigen-binding affinities of IgG isotype glycovariants, we titrated the antibodies on CD20 expressing human Raji-Burkitt’s lymphoma cells and analyzed binding by flow cytometry (Figure 2). For each isotype, galactosylated and degalactosylated glycovariants did not differ in their antigen-binding characteristics.

IgG-Fc Galactosylation of IgG1 and IgG3 Isotypes Increases C1q Binding and Complement-Dependent Cytotoxicity

The efficacy of IgG isotype-derived glycovariants to induce complement-dependent cytotoxicity (CDC) was determined in Burkitt’s lymphoma-derived Raji cells in the presence of active complement (human serum). Rituximab-derived IgG3 glycovariants showed the highest efficacy for CDC, followed by IgG1 (Figure 3). Glycovariants of IgG2 and IgG4 isotypes did not induce CDC. Galactosylation increased CDC mediated by both IgG1 (26% reduction of EC50) and IgG3 (13% reduction of EC50) but did not provide IgG2 and IgG4 with de novo ability to lyse target cells (Figure 3). To investigate the mechanism by which Fc-galactosylation impacts CDC, we determined the C1q binding affinities and kinetics of galactosylated and degalactosylated antibody variants (10). Incubation of CD20-expressing Raji cells in the presence of human serum depleted for C5, an essential component of the complement cascade, which allows to analyze the binding of members of the complement cascade to target cells while preventing cell lysis (10), led to rapid binding of C1q (Figure 4). Fc-galactosylation substantially enhanced the antibodies’ capacity to bind C1q for IgG1 and IgG3 isotypes (Figure 4). These data indicate that the addition of terminal galactose to the Fc-glycan enhances cell-depleting efficacies of human IgG1 and IgG3 isotypes through increased C1q binding.

Fc-Galactosylation Does Not Increase IgG:FcγRIIIa-Binding Affinities

Rituximab depletes B cells through a combination of CDC and antibody-dependent cell-mediated cytotoxicity (ADCC), which requires antibody binding to the human-activating FcγRIIIa (CD16) (10, 11). Absence of the IgG-Fc core fucose increases binding to FcγRIIIa (8, 12), a finding increasingly being used to improve the efficacy of therapeutic antibodies (13–15). Two studies reported that Fc-galactosylation results in a slight, albeit not statistically significant increase in FcγRIIIa-binding affinity and ADCC activity (16, 17). A more recent study confirmed that afucosylated glycoforms show higher binding affinities for FcγRIIIa, while Fc-galactosylation did not significantly impact FcγRIIIa binding (18). To investigate whether Fc-galactosylation of IgG isotype glycovariants increases binding affinities of IgG isotypes for FcγRIIIa, thereby potentially enhancing the antibodies’ ability to induce ADCC, we titrated IgG glycovariants onto CHO-derived cell lines recombinantly expressing FcγRIIIa. FcγRIIIa binding was strongest for IgG1 and IgG3 isotypes.
**DISCUSSION**

Initiation of the classical complement cascade through binding of Clq is a potent proinflammatory mechanism by which IgG antibodies trigger immune responses during infection and its deregulation causes tissue damage in a wide array of human inflammatory, degenerative, and autoimmune diseases (19). Our study shows that Fc-galactosylation enhances the efficacy of complement-fixing IgG isotypes to induce CDC through improved binding of Clq.

The antibody-dependent classical complement pathway is initiated if the C1 complex, formed by the multimeric pattern recognition molecule Clq and the modular proteases C1r and C1s, docks on antigen-bound IgG (20). Clq binds to monomeric IgG with very low affinity but antigen-driven antibody clustering allows for the formation of IgG hexamers that bind Clq with high avidity and promote efficient complement activation (21). The N-glycan resides in the CH2 domain, which is required for Clq binding (22). Sites on the surface of human IgG1 that constitute the Clq-binding epicenter are conserved in human IgG isotypes that are deficient in Clq binding and it has therefore been suggested that the composition of the N-glycan might be critical for the antibodies’ conformation and its ability to bind Clq (23).

Each biantennary oligosaccharide chain extends one arm toward the CH2–CH3 interface region and the other arm into the space between the CH2 domains, resulting in multiple interactions with the surface of the CH2 domain and the glycan of the opposing CH2 domain, respectively (4). Indeed, optimal Cl activation requires the presence of the Fc-glycan since Clq-mediated effector functions are compromised or lost in aglycosylated or deglycosylated IgGs (24–26). The effect of deglycosylation on reducing Clq binding has recently been attributed to its inhibition of IgG hexamerization via modulation of IgG Fc:Fc interactions rather than reduction of direct Clq-Fc-binding affinities (27). Based on these data and our results, we suggest that Fc-galactosylation modulates Fc:Fc interactions for antigen-bound IgG, thereby improving binding of Clq and increasing the antibodies’ ability to induce classical complement activation and CDC.

We systematically investigated whether Fc-galactosylation facilitates Clq binding and CDC effector functions across all human IgG isotypes. For murine IgG2b and IgG1, it has been demonstrated that addition of terminal galactose increases binding of Clq (28). While presence of terminal galactose enhanced complement activation by CD20 targeting, Clq-fixing human IgG1 and IgG3 isotypes, IgG2 and IgG4 remained deficient in initiating the classical complement cascade indicating that Fc-galactosylation alone is not sufficient for IgG2 and IgG4 to acquire complement-fixing properties.

Rituximab and therapeutic monoclonal antibodies (mAbs) that target tumor cells via ADCC or CDC are approved for the treatment of various cancers (29). B-cell depletion by CD20-targeting antibodies is also widely used for the treatment of autoimmune diseases (30). However, some patients do not sufficiently

**FIGURE 3** | Increased CDC of rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3 but not IgG2 and IgG4 upon Fc-galactosylation. Complement-dependent lysis of CD20+ target cells in the presence of galactosylated or degalactosylated human anti-CD20 IgG isotypes. Exemplary lysis curves and EC50 values of three independent experiments are shown. Statistical analysis: paired two-tailed Student’s t-test *p < 0.05, **p < 0.01.
**FIGURE 4** | Increased C1q binding of Fc-galactosylated rituximab-derived immunoglobulin gamma 1 (IgG1) and IgG3. Kinetic of C1q binding to CD20+ Raji cells in the presence of galactosylated or degalactosylated glycovariants of human IgG1–4. Exemplary C1q-binding curves (left), flow cytometry histograms of C1q binding after 60 min (center) and statistics at time point 60 min of at least three independent experiments. Statistical analysis: unpaired two-tailed Student's t-test, mean ± SEM, ns, not significant, *p < 0.05, **p < 0.01, and ***p < 0.001. MFI, median fluorescence intensity.
respond to rituximab therapy (31, 32) and improved versions of B cell depleting antibodies have been developed to increase ADCC activity and improve clinical efficacy (33, 34). Our data indicate that Fc-galactosylation, in addition to the established effect of defucosylation on ADCC, increases target cell cytotoxicity through enhancing CDC. Fc-galactosylation specifically improved binding of C1q to human IgG1 and IgG3 without changing antigen-binding affinities. Our data therefore indicate that Fc-galactosylation should be harnessed in glycoengineering therapeutic antibodies for effective antibody-dependent complement activation and target cell killing.

**MATERIALS AND METHODS**

**Buffers and Reagents**

Human serum complement (Cat. No.: A100; Lot No.: 035997) and C5-depleted human serum (Cat. No.: A501; Lot No.: 031795) were purchased from Quidel® Corporation. Accutase was purchased from StemCell Technologies Inc. (Cat. No.: 07920), Gibco™ RPMI-1640, HEPES (Cat. No.: 52400025), penicillin–streptomycin (P/S; 5,000 U/ml; Cat. No.: 15070063), LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Cat. No.: L34957), LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (Cat. No.: L10119), and TO-PRO-3 Stain (Cat. No.: T3605) were purchased from Invitrogen. Fetal calf serum (FCS) was purchased from Sigma-Aldrich (Cat. No.: F7524-500M; Lot No.: 051M3395) and from Bioswissotech (Cat. No.: S0615; Lot No.: 1047D). β1-4 galactosidase (Cat. No.: 345806-50MIU) and UDP-galactose (Cat. No.: 670111-50MG) were purchased from Merck Millipore Corporation, Calbiochem®. Protein-G sepharose was purchased from GE healthcare (Cat. No.: 17-0618-01). Biotinylated *Erythrina Cristagalli* lectin (Cat. No.: B-1145) and *Lens Culinaris* Agglutinin (Cat. No.: B-1045) were purchased from Reactolab. Phosphate-buffered saline (PBS; 2.68 mM KCl, 8 mM NaHPO₄, 1.8 mM KH₂PO₄, 137 mM NaCl, pH adjusted to 7.3) was produced in-house.

**Antibodies and Streptavidin**

Monoclonal mouse anti-human C1q (Cat. No.: A201) and biotinylated anti-human C1q (Cat. No.: A700) were purchased from Quidel® Corporation. Polyclonal rabbit anti-mouse IgG (H + L)-Alexa Fluor 488 (Cat. No.: A-11059) was purchased from Invitrogen. PE-conjugated streptavidin (Cat. No.: 405203) was purchased from Biolegend.

**CDC Assay**

Raji cells were used as CD20⁺ target cells to assess CDC. Accordingly, 7 × 10⁴ Raji cells were cultivated in RPMI-1640 containing P/S (50 U/ml) in a humidified incubator (37°C, 5% CO₂) in 96-well V-bottom plates. Cells were incubated with titrated concentrations of the respective galactosylated and degalactosylated anti-CD20 antibody isotypes. After 30 min, human serum complement was added to a final concentration of 5% and incubation was continued for another 12 h. Thereafter, cells were washed twice by adding 200 µl cold PBS and centrifugation at 400 × g and 4°C for 5 min. Cells were resuspended in cold PBS and TO-PRO3 stain (final concentration of 200 nM) was added to detect dead cells. All samples were analyzed on a BD FACSCanto-II using FACSDiva v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.). Specific lysis was calculated as percent increase in dead cells compared to spontaneous lysis in the absence of an anti-CD20 antibody. EC50 values were calculated via a non-linear regression in GraphPad Prism 5.

**C1q-Binding Assay**

A total of 2 × 10⁴ Raji cells were incubated with 10 µg/ml with galactosylated and degalactosylated anti-CD20 antibody isotypes in RPMI-1640 containing 1% P/S (50 U/ml) and 1% C5-depleted human serum for 5, 15, 30, or 60 min in a humidified incubator (37°C, 5% CO₂). After incubation with the different anti-CD20 antibody isotypes, cells were washed twice with 200 µl cold PBS, and C1q binding was determined by adding biotinylated anti-C1q antibody (25 µg/ml in PBS) for 1 h on ice followed by washing...
twice with 200 μl cold PBS and incubation with PE-conjugated streptavidin (1:400 in PBS) and dead cell stain (LIVE/DEAD Fixable Aqua Dead Cell Stain Kit; 1:250 in PBS) for 20 min. After washing twice with 200 μl PBS, samples were analyzed on a BD FACSCanto-II using FACSDiva v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.).

**CD20-Target-Binding Assay**

Raji cells were maintained in RPMI-1640 containing P/S (50 U/ml) and 10% FCS in a humidified incubator (37°C, 5% CO2). 1.2 × 10^6 Raji cells and anti-CD20 antibody isotypes and glycovariants were incubated for 25 min on ice. Dead cells were excluded using LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit. Cells were washed twice with 200 μl PBS and anti–mouse IgG (H + L)-Alexa Fluor 488 was added and incubated for 20 min on ice followed by two washing steps with 200 μl cold PBS. All samples were analyzed on a BD FACSCanto-II using FACSDiva v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.).

**FcγR-Binding Assay**

Human FcγRIIa-expressing CHO cells (35) were kindly provided by Falk Nimmerjahn (Department of Biology, University of Erlangen-Nürnberg, Germany). Cells were maintained in RPMI-1640 containing P/S (50 U/ml) and 10% FCS in a humidified incubator (37°C, 5% CO2). To detect binding of anti-CD20 antibodies, cells were detached using accutase, washed with cold PBS, and 2 × 10^6 cells were incubated on ice for 30 min with anti-CD20 antibodies. After incubation, cells were washed twice with 200 μl cold PBS and anti–mouse IgG (H + L)-Alexa Fluor 488 was added for 20 min on ice. All samples were washed twice with 200 μl cold PBS and analyzed on a BD FACSCanto-II using FACSDiva v6.1.3 software and FlowJo software v9.3.1 (Tree Star Inc.).

**Generation of Recombinant Monoclonal Anti-CD20 IgG Isotypes**

The DNA encoding for the N terminal region of the light chain (amino acids QIVLS until KLEIK) and heavy chain (amino acids QVQLQ until TVSAA) of rituximab were modified to encode for human IgG1, -2, -3 and -4 heavy chain (amino acids QIVLS until KLEIK) and heavy chain (amino acids QVQLQ until TVSAA) of rituximab (www.drugbank.ca; accession number FJ475056.1) using AgeI and κ-AbVec (NCBI GenBank accession number FJ475055.1) (36) was modified to encode for human IgG1 (allotype G1m17,1), IgG2 (allotype G2m), IgG3 (allotype G3m), and IgG4 (kindly provided by Lars Hangartner, the Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, CA, USA) for helpful discussion and reviewing the manuscript. All the authors cowrote and approved the manuscript.

**Statistics**

A p-value of 0.05 or less was defined as statistically significant. For all analyses, Prism software, version 5 (GraphPad Software, Inc.) was used. Specific statistical tests are indicated in the respective figure legends.

**AUTHOR CONTRIBUTIONS**

IQ and JL conceived the study. JL designed, BP, CK, and IQ designed and performed experiments. PW performed experiments. All the authors cowrote and approved the manuscript.

**ACKNOWLEDGMENTS**

We thank Lars Hangartner (The Scripps Research Institute, Department of Immunology and Microbial Science, La Jolla, CA, USA) and Michael A. Maurer (Brain Research Institute, University of Zürich) for providing human IgG1–4 expression vectors. We thank Lai-Xi Wang and Tiezheng Li (Department of Chemistry and Biochemistry, University of Maryland, MD, USA) for helpful discussion and reviewing the manuscript.

**FUNDING**

CK was supported by a scholarship provided by the German Research Foundation (DFG grant KE 1831/1-1) and a Forschungskredit provided by the University of Zurich (FK-14-021). IQ was supported by a DOC scholarship provided by the Austrian Academy of Sciences (ÖAW). JL was supported by the Swiss National Science Foundation (31003A-169664), the Novartis Foundation for medical-biological research, the Sasseila Foundation, the Hartmann Müller Foundation, and the Swiss Multiple Sclerosis Society.
REFERENCES

1. Shakh F, Stansworth DR. Human IgG subclasses in health and disease. (A review). Part I. *Ric Clin Lab* (1980) 10:463–79. doi:10.1007/BF02938793

2. Vidalasgon G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. *Front Immunol* (2014) 5:520. doi:10.3389/fimmu.2014.00520

3. Schwartz F, Aebl M. Mechanisms and principles of N-linked protein glycosylation. *Curr Opin Struct Biol* (2011) 21:576–82. doi:10.1016/j.sbi.2011.08.005

4. Krapp S, Mimura Y, Jeffers R, Huber R, Sondermann P. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. *J Mol Biol* (2003) 325:979–9. doi:10.1016/S0022-2836(02)01250-0

5. Pareek R, Roitt I, Isenberg D, Dwek RA. Age-related galactosylation of human Fc glycans. *J Proteome Res* (2003) 2:673–40. doi:10.1021/pr0206900

6. Dekkers G, Plopm R, Koelmaen CA, Visser R, von Horsten HH, Sandig V, et al. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. *Sci Rep* (2016) 6:36964. doi:10.1038/srep36964

7. Bakovic MP, Selman MH, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. *Sci Rep* (2016) 6:36964. doi:10.1038/srep36964

8. Diebold CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. Combination of IgG hexamers assembled at the cell surface. *Science* (2014) 343:1260–3. doi:10.1126/science.1249843

9. Duncan AR, Winter G. The binding site for C1q on IgG. *Nature* (1988) 332:738–40. doi:10.1038/332738a0

10. Quast I, Keller CW, Maurer MA, Lunemann JD. Generation of IgG-Fc glycovariants using Pichia pastoris. *PLoS One* (2015) 10:e0143520. doi:10.1371/journal.pone.0143520

11. Thoman M, Schloothauer T, Malic S, Avenal C, Bulau P, et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. *PLoS One* (2015) 10:e0134949. doi:10.1371/journal.pone.0134949

12. Li T, DiLillo DJ, Bourouzas S, Giddens JP, Ravetch JV, Wang LX. Modulating IgG effector function by Fc glycan engineering. *Proc Natl Acad Sci U S A* (2017) 114(13):3485–90. doi:10.1073/pnas.1702731114

13. Holers VM. Complement and its receptors: new insights into human disease. *Annu Rev Immunol* (2014) 32:433–59. doi:10.1146/annurev-immunol-032713-120154

14. Mortensen SA, Sander B, Jensen RK, Pedersen JS, Golas MM, Jensensius JC, et al. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. *Proc Natl Acad Sci U S A* (2017) 114:9386–91. doi:10.1073/pnas.1619988114

15. Thoman M, Schloothauer T, Derevitski T, Malik S, Avenal C, Bulau P, et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. *PLoS One* (2015) 10:e0134949. doi:10.1371/journal.pone.0134949